Detroit Free Press
Karmanos’ new president and CEO, Boris Pasche, M.D., Ph.D., FACP, is the co-inventor of the TheraBionic P1 device. This medical device received FDA approval in 2023 for the treatment of advanced hepatocellular carcinoma for patients who failed first- and second-line treatments. Karmanos will be the first cancer center to offer the device to patients in 2024. Dr. Pasche and Anthony Shields, M.D., Ph.D., medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology and the Phase 1 Clinical Trials Multidisciplinary Teams, explain how the device works to stop tumor growth.
Read the article here.
Boris Pasche, M.D., Ph.D., FACP
Anthony Shields, M.D., Ph.D.